BIBvsIBRN
ProShares Ultra Nasdaq Biotechnology against iShares Neuroscience and Healthcare ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| BIB | IBRN | |
|---|---|---|
| Expense ratio | 0.95% | 0.47% |
| Assets | $104M | $7864.21T |
| Net flow, 1 month | +$2M | +$2M |
| Net flow, 1 year | −$10M | +$2M |
| Return, YTD | +53.4% | +24.7% |
| Return, 1 year | +115.2% | +57.5% |
| Avg daily volume | 11K | 3K |
| Holdings | 229 | 54 |
| Listed | Apr 8, 2010 | Aug 23, 2022 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS